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Esme “Ezzy” Hodge, left, of Bristol, U.K., 
recently took her first independent steps 
following selective dorsal rhizotomy (SDR) 
surgery at St. Louis Children’s Hospital. 
Neurosurgeon T.S. Park, MD, has performed 
SDR on more than 3,700 patients with 
cerebral palsy worldwide. In most cases, the 
procedure permanently removes spasticity, 
enabling patients to walk again. See page 24.
COVER   Will Ross, MD, MPH, nephrologist 
and associate dean for diversity, grew 
up “the poorest of the poor.” His earliest 
memories are ones of violence. Today, he 
is a national leader speaking out against 
health disparities and has ingrained core 
principles of understanding and treating 
the underserved into the medical school 
curriculum. See page 18.
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Envisioning cells like little machines, 
Farshid Guilak, PhD, is reprogramming 
them to fight arthritis. In the lab, his 
team successfully has grown a living 
human hip ball joint that suppresses 
inflammation. See page 12.
A dedication ceremony recently was held for 
the Debra and George W. Couch III Biomedical 
Research Building. The couple’s $10 million gift 
supports one of the medical school’s highest  
priorities: personalized medicine. See page 30.
DEPAR TMENTS
 2  Pulse 
 
30    Alumni &  
Development  
  30  Personalizing  
medicine
  33 Classnotes 
  37  Flight surgeon’s  
storied career 
Washington University School of Medicine   
O U T L O O K . W U S T L . E D U    W I N T E R  2 0 1 7 - 1 8
174295_IFC-p1_TOC v6_cc17.indd   2 12/1/17   9:07 AM
2  Washington University School of Medicine
pulse









Zika virus kills glioblastoma stem cells in early research
B Y  T A M A R A  B H A N D A R I
W hile Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective 
treatment for glioblastoma, a deadly form of 
brain cancer. New research from Washington 
University School of Medicine and the University 
of California San Diego School of Medicine 
shows that the virus kills brain cancer 
stem cells, the kind of cells that are most 
resistant to standard treatments.
“We showed that Zika virus can kill 
the kind of glioblastoma cells that tend 
to be resistant to current treatments 
and lead to death,” said Michael S. 
Diamond, MD, PhD, the Herbert 
S. Gasser Professor of Medicine 
at Washington University and 
the study’s co-senior author.
The findings are published 
Sept. 5 in The Journal of 
Experimental Medicine.
The standard glioblastoma 
treatment is aggressive 
— surgery, chemotherapy 
and radiation — yet most 
tumors recur within six 
months. A small population 
of glioblastoma stem cells 
often survives the onslaught 
and continues to divide, 
producing new tumor cells to 
replace the ones killed by the 
cancer drugs.
In their neurological origins 
and near-limitless ability to create 
cells, glioblastoma stem cells reminded 
postdoctoral researcher Zhe Zhu, PhD, of 
neuroprogenitor cells, which generate cells  
for the growing brain. Zika virus specifically 
targets and kills neuroprogenitor cells.
Collaborating with co-senior authors  
Diamond and Milan G. Chheda, MD, of 
Washington University, and Jeremy N. Rich, MD, 
of UC San Diego, Zhu tested whether the virus 
could kill stem cells in glioblastomas removed 
from patients at diagnosis. They infected tumors 
with one of two strains of Zika virus. Both strains 
spread through the tumors, killing the cancer  
stem cells while largely avoiding other tumor cells.
The findings suggest that Zika infection 
and chemotherapy-radiation treatment have 
complementary effects. The standard treatment 
kills the bulk of the tumor cells but often leaves 
the stem cells intact to regenerate the tumor.  
Zika virus attacks the stem cells but bypasses  
the greater part of the tumor.
To find out whether the virus could help  
treat cancer in a living animal, the researchers 
injected either Zika virus or salt water (a placebo) 
directly into the brain tumors. Tumors were 
significantly smaller in the Zika-treated mice  
two weeks after injection, and those mice  
survived significantly longer.
The idea of someday injecting a virus 
notorious for causing brain damage into people’s 
brains seems alarming, but Zika may be safer 
for use in adults because its primary targets — 
neuroprogenitor cells — are rare in the adult brain.  
The fetal brain, on the other hand, is loaded with 
such cells, which is part of the reason why Zika 
infection before birth produces widespread and 
severe brain damage.
Outlook  3outlook.wustl.edu
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How did you come up with the idea of using  
Zika to treat glioblastoma?
Diamond: It was really the idea of Zhe Zhu, who 
was a postdoc with Jeremy Rich. He emailed me 
several times and said he wanted to do it. I said, 
“That’s crazy, I don’t want to do that.” Because  
I knew that a related virus — West Nile — had 
been tried 50 years ago and it made things worse. 
It caused serious brain infections and did not cure 
the cancer. So I said, “That’s not going to work. 
That’s not safe.” But he kept on asking until I 
agreed to let him try. Jeremy sent him over to my 
lab for what was supposed to be three months and 
turned into a year. And at some point we gathered 
enough data to look at which cells were being 
infected and found that it was not replicating 
throughout the brain and then I no longer had 
reservations. After we had established that the 
virus could specifically infect the stem cells, we 
needed someone with neuro-oncologic expertise. 
Milan took on a major role at that point.
What has been the response to the study?
Chheda: We’ve received emails from patients  
all over the world. They say that their loved  
ones or a friend or they themselves are in this 
dire situation and ask if they can try Zika.  
We tell them that it’s not FDA-approved, it hasn’t 
been proven safe or effective, but some people 
say they understand that and they want to try 
it anyway. We’ve been asked if we can bring the 
virus to some other place, like Mexico, where 
FDA rules don’t apply so they can try it. And of 
course we can’t do that, but it just goes to show 
how desperate people are for any bit of hope.
What do you say to the people who contact you?
Chheda:  I ask if they want to speak on the 
phone. They tell me about their current treatment  
or plans for treatment. The one thing that stands  
out is that throughout the world, almost everyone 
is treated the same way when they are first 
diagnosed. And universally the situation is dire 
no matter where you live. I tell them that we’re 
working on getting to human trials, but we’re 
talking about at least a year and a half before 
anything could potentially be tested in humans.
What do you have to do before you can test  
it in people?
Diamond: We are trying to get some guidance 
on that from the FDA. Because of the dire 
nature of the disease, the bar might not be as 
high as we thought. The key issue, of course, 
is safety. Although discussions are planned, 
the FDA likely will require that giving Zika 
doesn’t make things worse in mice, and that we 
can manufacture the virus according to good 
manufacturing practices. But they may want 
more, too; it’s not totally clear yet. 
From left, brain cancer stem cells before and after Zika 
treatment. A new study shows that the virus, known for 
killing cells in the brains of developing fetuses, could 
be redirected to destroy the kind of brain cancer cells 






with Mike Diamond and Milan Chheda
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iteman Cancer Center is one of the 
first U.S. centers to offer an immune 
therapy targeting advanced non-
Hodgkin lymphoma (NHL) in adults. Yescarta, 
a chimeric antigen receptor (CAR)-T cell 
therapy, is the second gene therapy approved 
by the Food and Drug Administration 
(FDA). Washington University doctors and 
researchers were involved in clinical trials 
leading to its approval.
In cancer patients, the immune system’s  
T cells lose the ability to recognize and attack 
cancer cells. CAR-T cell therapy involves 
isolating a patient’s T cells from the blood  
and genetically altering — or supercharging 
— those cells to home in on cancer cells.
Once a CAR-T cell finds its target, it 
behaves as any T cell should — triggering a 
chain reaction that destroys the cancerous 
cell. There is evidence that some CAR-T cells 
may maintain active surveillance and ramp 
up again in response to cancer recurrence. 
CAR-T cells can be programed to lock on to 
different cell surface features, suggesting the 
strategy could expand to other cancers.
Immune therapy targets certain blood cancers
S The therapy for NHL is available only to adult patients whose cancer has not responded to standard 
treatments, including chemotherapy 
and bone marrow transplantation. Kite 
Pharma developed the new treatment.
Because the therapy induces a 
heightened immune response, there 
can be a range of side effects, from 
fever and shortness of breath to 
kidney failure and seizures. Many of 
the side effects are manageable, but 
some are severe and a few can be 
life-threatening, which is why the first centers 
selected to administer the new therapy are 
those with extensive expertise in treating 
blood cancers.
The first cancers to be treated with 
CAR-T cell therapy include certain types of 
large B-cell lymphomas in adults and acute 
lymphoblastic leukemia (ALL) in children. 
Clinical trials of CAR-T therapy have shown 
what doctors have called remarkable 
remission rates among children with ALL 
and adults with lymphomas and multiple 
myeloma. In patients whose disease has 
not responded to standard therapies or has 
relapsed, CAR-T therapy has achieved from  
40 to 80 percent remission rates. Some patients 
have remained in remission for several years.
Doctors at Siteman also are evaluating  
or soon will be evaluating CAR-T therapy  
via clinical trials for sarcoma, melanoma,  
lung and ovarian cancer, leukemia and 
multiple myeloma. 
T cells are isolated from the blood and modified to 
home in on the type of cell affected by the cancer. 
New research has identified immune signaling molecules that 
may underlie chronic itching, an unrelenting urge to scratch.
The researchers also discovered that patients with chronic 
idiopathic pruritus, a type of itch from an unknown cause, 
improve when given the rheumatoid arthritis drug tofacitinib 
(Xeljanz). Earlier attempts to treat their itching with other 
anti-inflammatory 
drugs had been 
unsuccessful. Within 
one month of 
taking tofacitinib, all 
five study patients 
experienced marked 
relief: They stopped 
scratching, started 
sleeping again and 
returned to more 
productive lives. 
“Obviously, we’ll need to do a larger study, but the early results 
are very encouraging,” said Brian S. Kim, MD, an assistant professor 
of medicine and co-director of the Center for the Study of Itch. 
As part of the study, the researchers showed that the 
immune signaling molecule interleukin-4 (IL-4) activates 
sensory neurons in mice and people. IL-4 signaling can 
jumpstart chronic itching in the setting of inflammation 
but also independently of pathways directly linked to 
inflammation, they found. Chronic idiopathic pruritus, for 
example, isn’t associated with inflammation.
Kim’s team, led by MD/PhD student and first author Landon 
K. Oetjen, engineered mice to have sensory neurons that 
lacked the ability to respond to IL-4. When exposed to stimuli 
that should have made them itch, the mice didn’t scratch.  
The researchers then determined that IL-4 stimulates 
JAK1, a key protein within nerve cells that may be a uniquely 
sensitive target for multiple types of itch. The drug tofacitinib 
blocks this protein.





















HYcientists working to develop 
treatments for neurodegenerative 
diseases have been stymied by the 
inability to grow human motor neurons in the 
lab. Motor neurons drive muscle contractions, 
and their damage underlies devastating 
diseases such as amyotrophic lateral sclerosis 
and spinal muscular atrophy.
Now, School of Medicine scientists have 
converted skin cells from healthy adults 
directly into motor neurons without going 
through a stem cell state.
The technique makes it possible to study 
motor neurons of the human central nervous 
system in the lab. Unlike commonly studied 
mouse motor neurons, human motor neurons 
growing in the lab would be a new tool since 
researchers can’t take neuron samples from 
living people but can easily take skin samples.
Avoiding a stem cell state allows the 
resulting motor neurons to retain the age  
of the original skin cells and, therefore, 
the age of the patient. Maintaining the 
chronological age of these cells is vital when 
studying neurodegenerative diseases that 
develop in people at different ages and 
worsen over decades.
Skin cells turned into human motor neurons
S “In this study, we only used skin cells from healthy adults ranging in age from 
early 20s to late 60s,” said 
senior author Andrew S. Yoo, 
PhD, an assistant professor 
of developmental biology. 
To convert skin cells 
into motor neurons, the 
researchers exposed the 
skin cells to molecular 
signals that are usually 
present at high levels in the 
brain. Past work by Yoo and 
his colleagues — then at 
Stanford University — showed that  
exposure to two short snippets of RNA,  
called miR-9 and miR-124, turned human  
skin cells into neurons. 
After much experimentation, researchers 
found that adding two more signals to the 
mix — transcription factors called ISL1 and 
LHX3 — turned the skin cells into spinal cord 
motor neurons in about 30 days.
The combination of signals tells the cell 
to fold up the genetic instructions for making 
skin and unfurl the instructions for making 
motor neurons.
The researchers said the converted motor 
neurons compared favorably to normal mouse 
motor neurons. Future work studying neuron 
samples donated from patients after death 
is required to determine how precisely these 
cells mimic native human motor neurons.
Although 29 states and the District of Columbia allow 
marijuana use for medical purposes, few medical students  
are being trained how to prescribe the drug, according to 
School of Medicine research. 
The research team, led by first author Anastasia B. 
Evanoff, a third-year medical student, sent surveys to 
curriculum deans at 172 medical schools in North America, 
including 31 that specialize in osteopathic medicine, and 
received 101 replies. Two-thirds reported that their graduates 
were not prepared to prescribe medical 
marijuana. A quarter of deans said their 
trainees weren’t even equipped to answer 
questions about medical marijuana.
The researchers also surveyed 258 
residents and fellows 
who earned their medical degrees from schools around the 
country. Nearly 90 percent felt they weren’t prepared to 
prescribe medical marijuana, and 85 percent said they had not 
received any education about the drug during medical school 
or residency.
In examining a curriculum database maintained by the 
Association of American Medical Colleges, the researchers 
found that only 9 percent of medical schools had reported 
teaching their students about medical marijuana.
“Medical education needs to catch up to marijuana 
legislation,” said senior author Laura Jean Bierut, MD, the 
Alumni Endowed Professor of Psychiatry and a member of 
the National Advisory Council on Drug Abuse. “Physicians 
in training need to know the benefits and drawbacks 
associated with medical marijuana so they know when or  
if, and to whom, to prescribe the drug.”
Medical students not trained to prescribe marijuana
Scientists have discovered a new way to convert 
human skin cells directly into motor neurons (above). 
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The Chan Zuckerberg Initiative has awarded pilot 
grants to two School of Medicine researchers, 
supporting projects contributing to the Human Cell 
Atlas. This is an international effort to create a detailed 
map of all cells in the human body. Charting the 
locations of individual cells, unraveling their genetics 
and revealing how they interact to regulate health can 
shed light on how things go wrong and result in disease.
Facebook co-founder Mark Zuckerberg and his 
wife, Priscilla Chan, MD, established the Chan 
Zuckerberg Initiative with the goal of eliminating 
disease. 
Samantha A. Morris, PhD, an assistant professor  
of developmental biology and of genetics, and 
Benjamin D. Humphreys, MD, PhD, the Joseph 
Friedman Associate Professor of Renal Diseases in 
Medicine, each have received one year of support to 
conduct single-cell RNA sequencing with a focus on 
cells in the kidney, liver and small intestine. Their labs 
will map out the relationships between and plumb 
the biological depths of every one of the millions of 
individual cells that make up each of those organs.
Humphreys, a kidney specialist, is investigating why 
some patients with diabetes experience kidney failure 
quickly while others gradually develop kidney damage. 
Morris is focused on cells in the liver and small 
intestine. A goal of her research is to engineer 
a working intestine as a therapy for short bowel 
syndrome. The condition can lead to malnutrition 
after a portion of the bowel has been removed, often 
to treat conditions such as cancer or Crohn’s disease.
Facebook CEO supports 












Before symptoms become pronounced, there is no reliable 
way to identify who is on track to develop Parkinson’s 
disease, a debilitating movement disorder.
But School of Medicine researchers have analyzed 
Medicare claims data of more than 200,000 people to 
develop an algorithm to predict whether a patient one day 
will be diagnosed with Parkinson’s. The algorithm relies on 
information in patients’ medical records, such as tests and 
diagnoses of various medical conditions.
“Using this algorithm, electronic medical records could 
be scanned and physicians could be alerted to the potential 
that their patients may need to be evaluated for Parkinson’s 
disease,” said Brad 
A. Racette, MD, 
the Robert Allan 
Finke Professor  
of Neurology  
and the study’s 
senior author. 
“One of the 
most interesting 
findings is that 
people who are 
going to develop 
Parkinson’s 
have medical 
histories that are 
notably different 
from those who 
don’t develop the disease. This suggests there are lifelong 
differences that may permit identification of those likely  
to develop the disease decades before onset.”
The study is available online in the journal Neurology.
Many of the claims codes referred to problems 
already known to be associated with Parkinson’s such as 
tremors, posture abnormalities, psychiatric or cognitive 
dysfunction, gastrointestinal problems, sleep disturbances, 
fatigue and trauma, including falls. Other factors 
associated with the disease included weight loss and 
multiple forms of chronic kidney disease.
In the 18 months before diagnosis, people endured a 
flurry of doctor visits and medical tests. Most likely, their 
symptoms were worsening, and their doctors were running 
test after test, looking for the cause, said Racette. Using 
this algorithm potentially could help reduce unnecessary 
tests and speed the process of diagnosis, he said.
Algorithm could speed 
Parkinson’s diagnosis
In single-cell RNA sequencing, individual cells are suspended in water 
droplets that contain a coated bead. When the cell is purposefully broken 
apart, the coated bead captures the cell’s RNA so it can be analyzed. Above, 
the large circles are water droplets. Smaller, dark circles are the coated 
beads. In the center, a single translucent kidney cell from a mouse touches 
one of the beads. Each droplet is about the diameter of a human hair.
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Researchers are studying the use of nitrous oxide — 
laughing gas — as a treatment for patients who are 
hospitalized due to suicidal thoughts. 
Most standard antidepressant drugs affect norepinephrine 
and serotonin receptors in the brain, but can take weeks to 
improve a person’s symptoms. Nitrous oxide interacts with a 
different type of 
receptor in the 















professor of anesthesiology and of genetics. “The gas has 
very few side effects because it leaves the body very quickly 
once people stop breathing it. However, it appears from our 
previous research that the antidepressant effects of nitrous 
oxide may linger in the brain long after the drug is out of  
the body.”
In this new study — funded by a grant from the 
American Foundation for Suicide Prevention — people who 
have attempted suicide will breathe a mixture of oxygen and 
nitrous oxide for one hour, every other day, for one week.
Half of the anticipated 50 study patients will receive this 
mixture; the other half will receive oxygen — but without 
the nitrous oxide — over the same amount of time. All 
participants will receive antidepressant drugs or talk therapy 
normally prescribed during such a hospitalization. 
Ongoing follow-up visits will monitor the participants’ 
mental state. “If such problems re-emerge, the study is 
designed to provide ‘booster’ treatments with nitrous oxide, 
which we believe will continue to lower the likelihood of 
future suicidal thoughts,” said Charles R. Conway, MD,  
a professor of psychiatry.
Can laughing gas help 
prevent suicide?
Enjoy interactive elements and 
added content
Good fat in our bodies helps burn calories, while the bad 
fat hoards calories, contributing to weight gain and obesity. 
New research has identified a way to convert bad, white fat 
into good, brown fat, at least in mice.
White fat stores calories and pads our bellies, hips and 
thighs. Brown fat, found near our necks and shoulders, 
burns calories through a process that generates heat.
Beige fat — an intermediary between white and brown 
fat — was discovered in adult humans in 2015. It functions 
more like brown 
fat and can protect 
against obesity, said 
first author Irfan 
J. Lodhi, PhD, an 
assistant professor 
of medicine in 




His team created  
a genetic strain of 
mice that didn’t  
make a specific protein called PexRap in white fat cells.  
The researchers found that blocking the protein triggered  
the white fat to begin to brown into beige fat, causing the 
fat cells to burn calories. The mice with more beige fat were 
leaner than their littermates, even when they ate the same 
amount of food. They also burned more calories.
Lodhi said if PexRAP could be blocked safely in human 
white fat cells, people might have an easier time losing weight.
Scientists convert bad body fat 
in mice into good fat
Scott J. Hultgren, PhD, the Helen 
L. Stoever Professor of Molecular 
Microbiology, has been elected to the 
National Academy of Medicine, a part 
of the National Academy of Sciences. 
Membership is one of the highest 
honors in the field of medicine.
Hultgren has made groundbreak-
ing contributions to understanding 
urinary tract inf ctions. 
Hultgren elected to National 
Academy of Medicine
White fat cells from a normal mouse, left, and from 
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odents that lack a gene linked to 
autism form too many connections 
between neurons and have 
difficulty learning, according to a School of 
Medicine study. The findings suggest that 
some autism symptoms may stem from 
miscommunication among brain cells.
“This study raises the possibility that there 
may be too many synapses in the brains 
of patients with autism,” said senior author 
Azad Bonni, MD, PhD, the Edison Professor of 
Neuroscience and head of the Department of 
Neuroscience. “You might think that having 
more synapses would make the brain work 
better, but that doesn’t seem to be the case.”   
Autism, a neurodevelopmental disorder, 
is characterized by social and communication 
challenges. 
Of the many genes linked to autism, six 
are known as ubiquitin ligases because they 
attach a molecular tag, called ubiquitin, to 
Too many brain connections 
may be at root of autism
R proteins. These tags function like a work order, telling the rest of the cell how to deal with the tagged proteins: This one should 
be discarded, that one should be rerouted to 
another part of the cell.
Some people with autism carry a mutation 
that prevents one of their ubiquitin genes 
from working properly. But it is poorly 
understood how problems with tagging 
proteins affect the brain’s hardwiring and 
operation, and why such problems may  
lead to autism.
To understand the role of ubiquitin 
genes in brain development, Bonni, first 
author Pamela Valnegri, PhD, and colleagues 
removed the ubiquitin gene RNF8 from 
neurons in the cerebellums of young mice.
Neurons without RNF8 formed about  
50 percent more functioning synapses — the 
connections that allow neurons to send signals 
to each other — than those with the gene.
The cerebellum is indispensable for 
movement and learning new motor skills. 
Some common symptoms of autism —  
such as motor incoordination and a tendency 
to walk tippy-toed — involve control of 
movement.
The animals missing the RNF8 gene 
walked normally and appeared coordinated, 
but were unable to learn new motor skills.
The researchers since have tested other 
autism-associated ubiquitin genes. All of 
them led to an increase in synapses when 
inhibited, suggesting that too many synapses 
could be the reason why these genes are 
linked to autism. If this hypothesis proves true 
in people, finding ways to control the number 
of synapses might benefit those with autism.
Mutations in a gene linked to autism cause  
neurons to form too many connections in 
rodents. The findings suggest that malfunctions 
in communication between brain cells could be 
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STEPHEN LIANG, MD
Assistant professor of medicine and  
of emergency medicine 
Liang responded to Hurricane Harvey as a member of 
Missouri Task Force 1, part of the Federal Emergency 
Management Agency’s (FEMA) National Urban Search 
& Rescue Response System. As Harvey made landfall in 
Houston, FEMA called on Missouri Task Force 1 to deploy a 
team specialized in swift-water rescue. The task force rescued 
or evacuated about 400 people, as well as many pets. Liang 
was principally responsible for keeping the team healthy as it 
conducted strenuous operations. He also conducted medical 
checks on people brought to safety by his teammates. 
DOUGLAS CHAR, MD
Professor of emergency medicine
A team member with the 
National Disaster Medical 
System (NDMS), Char 
serves as the medical  
director of a Missouri 
group of more than 100 
doctors, nurses, paramed-
ics and other health-care 
professionals. During 
Hurricane Harvey, Char’s 
group was assigned to 
Dallas. Later, he traveled 
to Austin as chief medical 
officer and consultant for a 
U.S. Department of Health 
and Human Services (HHS) 
team handling hurricane-related flooding in Texas  
and Louisiana. He helped decide which shelters needed  
medical services and for how long, and compiled reports  
on disease outbreaks. After two weeks, he flew to Washington,  
serving as the overnight chief medical officer — dealing with 
Hurricanes Harvey, Irma and Maria — in the HHS crisis 
room, which is staffed 24 hours a day in national emergencies. 
Medical school physicians, 
staff aid hurricane victims
Washington University faculty and staff helped with emergency relief efforts after devastating 
hurricanes hit the southern U.S. and the Caribbean this summer. While they were away, their 
colleagues pulled together to keep operations on the Medical Campus running as normal.
Stephen Liang, MD, center foreground, and teammates in Missouri Task Force 1.
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JACOB KEEPERMAN, MD
Assistant professor of anesthesiology  
and of emergency medicine
Keeperman serves as a member of the Midwest-1 Disaster 
Medical Assistance Team of the NDMS and works part  
time for Air Evac Lifeteam, a national helicopter emergency 
medical services company. As the Missouri medical director  
of an Air Evac operations team, he decides which aircrafts  
get sent to affected areas and what protocols will be followed. 
After Hurricane Harvey, Air Evac sent 16 aircraft from 
throughout the national fleet to Houston. There, team  
members delivered patients from flooded hospitals to dry 
medical centers, and patients in need of dialysis to dialysis 
centers outside of Houston. The company also sent aircraft  
to Florida in response to Hurricane Irma.
JIM FEHR, MD
Professor of anesthesiology and of pediatrics
In hurricane-ravaged Puerto Rico, Fehr’s main job as part of 
the federal government’s Disaster Medical Assistance Team 
(DMAT) was to deal with nonemergency and logistical needs 
so health-care workers on the island commonwealth could 
concentrate on providing care to the sickest, most desperate  
residents. Fehr’s team, including nurses from Barnes-Jewish 
Hospital and St. Louis-area physicians, pharmacists and 
paramedics, worked to prevent indirect deaths related to 
Hurricane Maria. Indirect deaths include, for example, a 
patient who dies because storm-damaged roads prevent her 
from refilling a life-saving prescription — or the loss of a 
patient who is dependent on a kidney dialysis machine in  
the midst of a power outage.
TY DAVISSON
Director of emergency 
management and 
business continuity
Davisson, deployed  
to Puerto Rico with 
NDMS, helped coor-
dinate the federal  
government’s response 
to Hurricane Maria 
from an emergency 
command center in the 
San Juan Convention 
Center. For three weeks, he managed teams of medical 
staff (more than 1,000 people in all), mortuary workers,  
and public and behavioral health experts. To ensure an  
efficient medical response, each day the team planned,  
evaluated and tracked resources, determining where 
resources should go the following day.
Air Evac Lifeteam sent a Missouri crew to 
Texas following Hurricane Harvey. 
Ty Davisson, center, leads a meeting with federal 
response partners.
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Replacing a human joint is common, artificial and 
far from permanent. The procedure involves cutting 
into the body to remove living bone and replacing it 
with metal and plastic. As these parts typically last 
15 to 20 years, a second — riskier — replacement 
surgery sometimes is necessary. 
However, for a million Americans a year in 
agony with knee or hip arthritis, such implants are 
welcome. Because once cartilage, the tissue lining and 
lubricating joints, wears away, the patient is left with 
bone-on-bone pain, swelling, stiffness and disability. 
School of Medicine researchers are working on a 
radically different way to help people with arthritis: 
creating living joint replacements from the patient’s 
own cells and then programming those cells to fight 
an arthritis recurrence. 
Farshid Guilak, PhD, and collaborators have 
successfully grown part of a living human hip joint 
in the lab and now are testing the methodology in 
animals. The development ultimately could transform 
how arthritis and some orthopedic conditions are 
treated. Moreover, aspects of the research have 
implications for a host of other diseases.
Lab-grown 
cartilage 
Engineered stem cells could revolutionize  
arthritis therapy and  joint replacement
B Y  J I M  D R Y D E N
Stem cells, stained green, grow throughout  
the pores of a fabric scaffold, stained red,  
that is molded in the shape of a hip joint.  
After being treated with chemicals, the cells 
turn into cartilage. Eventually, the scaffold 
melts away, leaving a living replacement joint. 
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F or Guilak, it all began with envisioning cells as machines.“My background is in engineering, 
but I’ve always worked on cells,” said Guilak, a 
professor of orthopaedic surgery, of developmental 
biology and of biomedical engineering. “Cells 
are the basis of life, but they also are like little 
machines. They have motors. They store things 
like computers do, and they can generate forces 
and crawl around and pull on things. 
“They’re little machines that happen to be 
alive, and we thought, ‘Why not treat them like 
machines and reprogram them to become what 
we want them to be?’ And our first thought was 
to make cells into things that can treat diseases 
automatically.”
Guilak, also the co-director of the Washington 
University Center of Regenerative Medicine and 
director of research for Shriners Hospitals for 
Children-St. Louis, is working in a field known 
as synthetic biology. Combining aspects of 
engineering and biology, researchers design  
and build new cellular components to do 
something different from what they do in nature. 
Guilak manufactures cells programmed to 
combat arthritis. His lab is one of the few labs in 
the world doing this type of work. Until now, most 
synthetic biology research has been conducted in 
bacteria, which are easier to modify than cells.
“We began to work in mammalian cells, and it 
was difficult when we first started, but we got very 
lucky because as we were launching this research, 
the technique called CRISPR/Cas9 came on the 
scene, allowing us to quickly edit the genes in 
these cells,” Guilak said. 
CRISPR/Cas9 technology enables researchers to 
alter DNA sequences and modify gene function.
Regrowing cartilage
Starting this process requires the manufacture 
of a basic building material: human cartilage. 
First, Guilak’s laboratory acquires stem cells from 
skin or subcutaneous body fat via liposuction. 
Then, the researchers treat those stem cells with 
substances that convert them into particular cell 
types. “If you pull those cells out of the body and 
give them a very defined set of proteins and genes, 
they’ll start to make cartilage or bone or even 
muscle,” Guilak said.
In this case, researchers treat the stem cells so 
that they grow into cartilage, one of the principal 
tissues damaged by arthritis. 
But Guilak’s team was not content to use stem 
cells of ordinary “intelligence;” the researchers 
wanted to make them smarter. Using the gene-editing 
tool CRISPR/Cas9, the researchers excised a gene in 
From left, Guilak,  
Shannon O’Connor,  
an MD/PhD candidate,  
and Lara Pferdehirt,  
a PhD student, examine 
samples from a recent  
stem cell study.
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the cells associated with inducing inflammation and 
replaced it with a gene that dampens it. They dubbed 
these cells as “SMART” (Stem cells Modified for 
Autonomous Regenerative Therapy).
Inflammation is associated with all forms of  
arthritis and triggers much of its pain and discomfort.  
Osteoarthritis is a degenerative, inflammatory 
condition caused by wear and tear on specific 
joints. Rheumatoid arthritis, an autoimmune 
disorder, occurs when the immune system attacks 
tissues in joints as if they were foreign invaders. 
Through an analysis of arthritic cartilage, 
Guilak’s former student Jonathan Brunger, 
PhD, found that a particular gene, activated by 
inflammation, sparks further inflammation in 
response to a molecule called tumor necrosis 
factor-alpha (TNF-α). This molecule is primarily 
responsible for the inflammatory response in 
rheumatoid arthritis. Several available drugs block 
the TNF pathway to treat arthritis. 
“These drugs work in about half of all patients,” 
Guilak said, “but they’re given at high doses 
continuously, even though the disease waxes and 
wanes. What you really want is something that’s 
only given when there is a flare in the disease.”
Such medications reduce inflammation, but also 
carry side effects; they can suppress the immune 
system, affecting the body’s ability to fight infection. 
The gene that Guilak and Brunger inserted into 
the cartilage cells is activated only during bouts of 
arthritis inflammation, targeting the same pathway 
as the drugs Enbrel, Humira and Remicade. “We 
can control how a cell reacts to the external signals it 
receives,” Guilak said. “We can use CRISPR/Cas9 to 
make new logic circuits inside a cell. 
“In this case, it’s called a closed feedback loop 
because the cell has the capacity to shut down 
something that’s happening in its environment. 
Instead of encountering an inflammation signal 
and amplifying it to get bigger and bigger, which is 
what happens in arthritis, now when these SMART 
cartilage cells see this inflammatory molecule, they 
make the drug inhibitor to block it.”
Arthritis and beyond
Guilak’s team is working to combat the differing 
types of arthritis. Solutions range from a living 
joint replacement made with SMART cells for 
localized osteoarthritis to a possible implant or 
vaccine for the systemic disorder rheumatoid 
arthritis. Encased SMART cells could be placed 
under the skin the same way Norplant birth-control 
LIVING JOINT 
Resurfacing the joint with newly 
grown human cartilage potentially 
could last longer with fewer side 
effects. Engineered cells could  
prevent an arthritis recurrence.
HEALTHY HIP JOINT 
Healthy, smooth cartilage 
absorbs energy, bears weight 
and lubricates the joints for 
easy movement.
ARTHRITIC HIP JOINT
Degenerating cartilage results 
in bone-on-bone pain, swelling 
and stiffness.
ARTIFICIAL HIP JOINT
An artificial prosthesis eases 
pain and restores mobility but 
wears out in 15 to 20 years.
Treating degenerative joint disease
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SMART CELLS
With gene-editing technology, 
the stem cells are rewired to 
fight arthritis.
STEM CELLS
Stem cells are acquired from  
the skin or from subcutaneous 
body fat via liposuction. 
Rebuilding a human hip
One day, researchers may be able to resurface an arthritic joint  
using a patient’s own stem cells. 
SC AFFOLD
Cells are placed onto a porous,  
woven fabric molded into the  
shape of a hip ball. The cells  
permeate the fabric as it  
melts away.
C ARTIL AGE
Following a chemical  
treatment, the cells  
change into cartilage. 
SYNTHE TIC HIP JOINT
Newly grown cartilage, with  
the ability to produce an anti-
inflammatory drug, could keep  
the hip moving for years to come. 
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Using MRI images, the researchers can mold 
the fabric into the precise shape of a patient’s joint 
and seed it with stem cells. “Over a six-week period, 
the cells go inside the fabric, start growing, and are 
given chemicals that turn them into cartilage cells. 
The fabric eventually melts away, leaving a hip made 
out of your own cells,” Guilak said. “In the future, 
this technique could be used for any joints.”
The weaving pattern makes the implant strong 
enough to withstand loads up to 10 times a patient’s 
body weight — the standard force during exercise.
Guilak and the other researchers patented the 
weaving technique and formed a start-up company, 
Cytex Therapeutics Inc. 
His laboratory has demonstrated the 
technique works in human cells in culture, and 
he’s conducting animal studies that look very 
promising. As a result, Guilak has won the Arthritis 
Foundation’s highest award, and the Proceedings of 
the National Academy of Sciences has published the 
findings. If those trials remain successful, human 
safety studies could begin in three to five years.
Despite worldwide media attention on the 
research, Guilak said he is most motivated by his 
daily walk to work. “Part of our lab is at Shriners 
Hospitals for Children,” he said. “And we see so 
many kids come through with difficult problems. 
They have a whole lifetime ahead, but almost 
everything we do for them is temporary, or it’s 
something like a metal-and-plastic implant, which 
isn’t a great treatment for a child who will outlast 
those implants several times over. 
“Seeing those kids is part of what drives us to 
find better solutions. Our concept is that we can 
make cells that are like tiny computers that sense 
what’s causing problems and act accordingly.
 “We’re confident we’re on the right track.”
devices deliver hormones to prevent pregnancy for 
several months or years at a time. Likewise, because 
this strategy heightens immune response, a vaccine 
might be an effective biological treatment. 
In all of these scenarios, it’s possible, Guilak, 
said, that a patient could turn the gene on and off as 
needed by taking a pill. The idea is to protect the body 
both from inflammation and excessive medication. 
One of Guilak’s principal collaborators is 
Christine T. Pham, MD, a professor of medicine 
who treats patients with rheumatoid arthritis. 
Her lab has developed several mouse models of 
the disease, allowing researchers to test different 
treatment methods. 
The researchers also have set their sights well 
beyond arthritis. Already, they are thinking about 
cellular feedback loops to deliver substances to 
fight other disorders, for example, cells that could 
be engineered to release insulin in response to 
high blood glucose. 
For now, however, the primary strategy involves 
creating living cartilage from a person’s own stem 
cells to ease pain and keep the disorder at bay. 
A living prosthesis
Removing a worn-out artificial prosthetic can destroy  
the attached bone and put patients at risk for 
infection. Because of this, doctors are reluctant 
to perform artificial joint replacement in patients 
under age 50, leaving children and young adults 
with few options. Rising rates of obesity and 
arthritis mean that more people in their 40s are 
needing hip replacements. 
SMART cartilage fashioned in the form of a 
living joint potentially could outlast those made of 
metal or plastic. Researchers also believe there’s a 
lower risk of rejection because the cartilage cells are 
taken directly from the patient. 
Stem cell treatments for osteoarthritis began as 
early as 2008. Mostly, doctors have injected stem 
cells directly into affected areas, hoping the cells 
would stay in place and turn into cartilage. But this 
method has proven unsuccessful, as the cells tend to 
float away within a couple of weeks.
Guilak has spent years working on a method 
to keep the new cartilage cells in the joint. Before 
coming to Washington University, he and his Duke 
University colleagues developed a way to weave 600 
bio-compatible fibers approved by the U.S. Food 
and Drug Administration into a porous, high-
performance fabric scaffold. 
Christine T. Pham, MD, one 
of Guilak’s collaborators, is 
a professor of medicine who 
treats patients with rheu-
matoid arthritis. Her lab has 
developed mouse models 
of the disease, allowing 
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Will Ross knows he should be dead. Before his teen years, 
he had been beaten and bloodied countless times and 
stabbed in the arm. He had witnessed an execution-style 
murder and had watched riots burn his community.
He had hidden in his house to avoid gangs. Indoors, 
he often buried himself in books to escape the alcohol-
fueled fighting between his mother and her boyfriends.
“We were the poorest of the poor,” Ross said. 
“However, my experiences with violence were not  
unique. Most of the kids I knew growing up are dead  
or in jail. It is not hyperbole to say I should be dead.”
Now an esteemed nephrologist at the School 
of Medicine, Ross, MD, MPH, has achieved a level 
of success that he had never imagined as a boy 
scrounging for food and wearing ill-fitting hand- 
me-downs and fearing that rats would crawl over  
him in his sleep. 
Leading 
 with
   empathy
 The transformative influence of a doctor  
who hasn’t forgotten his past
















As part of an orientation 
program he designed,  
Will Ross, MD, MPH, exposes  
first-year medical students  
to blighted St. Louis neighbor-
hoods — not unlike the ones 
of his own childhood.   
Outlook  19
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R oss could easily ignore people living in communities like the ones of his childhood. But he won’t. His early 
experiences inspire him as a physician, a professor 
of medicine and as associate dean of diversity. 
Long before buzzwords such as “health equity” 
emerged in the medical field, Ross was teaching 
how health outcomes are compromised by race, 
gender, sexual orientation, income, housing, 
education and other factors.
Through collaborations with local health 
agencies, Ross has initiated dozens of programs 
aimed at providing medical care to those who 
cannot afford it and at improving community 
resources necessary for good health, such as 
transportation to a health clinic or access to fresh 
fruits and vegetables. 
“Humanity is lacking in neighborhoods like  
the one I grew up in,” Ross said. “I understand  
the social and economic barriers and the anger 
rooted in the violence. As physicians, we must  
be aware of such obstacles to health care.” 
Ross has ingrained these core principles of 
understanding and treating underserved patients 
into the medical school curriculum. He founded  
the Saturday Neighborhood Health Clinic for 
the sick and uninsured. More than 90 percent of 
Washington University medical students volunteer 
and gain practical, hands-on experience at the 
federally qualified, no-cost clinic. With faculty 
supervision, the students treat about 300 patients 
annually for ailments such as diabetes, asthma, high 
blood pressure and sexually transmitted diseases. 
“Regardless of medical specialty interests, all 
students benefit from learning about public health, 
and not just from a clinical perspective,” Ross said. 
“It teaches compassion and empathy. This is part 
of our moral responsibility as a medical school.”
The same year Ross founded the Saturday 
Neighborhood Health Clinic — in 1996 — he  
also became the associate dean for diversity.
“Will Ross is empathetic, enthusiastic and 
brilliant, and as associate dean for diversity, he  
has been nothing short of phenomenal,” said 
William Peck, MD, the Alan A. and Edith L. Wolff 
Distinguished Professor of Medicine and co-director  
of the Center for Health Economics and Policy. 
Peck, who served for 14 years as executive 
vice chancellor and dean of the medical school, 
recruited Ross to the position. 
“I knew right away that he was the person for 
the job,” Peck said. “Dr. Ross seems laid back, 
but he isn’t. He is strategic and determined in his 
trailblazing efforts. He has helped to transform 
public health care in St. Louis, the state, the country 
and the world, all while elevating Washington 
University in diversity and medical education.”
Plunging into reality
Ross’s influence on every student is visible 
beginning Day One. He created a mandatory, 
four-day orientation program for incoming 
medical students that includes a diversity  
retreat, lectures in health disparities and tours 
of St. Louis’ poorest, most racially segregated 
nonwhite neighborhoods. Called Washington 
University Medical Plunge, the course removes 
students from academic and clinical settings 
and immerses them into the realities facing 
underprivileged patients.
On the tour, students see abandoned and 
dilapidated homes, weedy parks where feral dogs 
roam and a lack of basic services such as markets 
with healthy food.
“It defines the abstract,” Ross said. “There’s no 
sugar-coating. Some of the students have never 
witnessed poverty before the tour. It’s important 
to broaden their outlook because they may one 
day treat patients in similar circumstances.”
The tour leaves many students teary-eyed and 
emotionally altered. “It had a major impact on me 
professionally,” said surgical resident Leisha Elmore, 
MD ’13, MPHS. “I found my love for serving 
underprivileged communities because of Dr. Ross.”
Similarly, many Washington University students 
have said they chose the School of Medicine 
specifically because of Ross, who is known for 
keeping his office door open and spontaneously 
inviting them to his house, where he and nurse 
anesthetist Arlene Moore, his wife of nearly  
30 years, raised two daughters. Both daughters  
are now adults dedicated to social justice. 
“ Humanity is lacking in neighbor-
hoods like the one I grew up in ... . 
As physicians, we must be aware  
of such obstacles to health care.” 
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Ross is noted for his calm demeanor and dapper 
clothing choices. He received his first bowtie for 
Easter when he was 4 years old. It’s a fond memory 
that has contributed to a collection of 50 bowties. 
At first glance, Ayodamola Otun, a first-year 
medical student from Nigeria, said he wondered if 
the distinguished professor with the bowtie would 
have time for him. “I thought Dr. Ross wouldn’t be 
interested in me because he had lived in privilege 
long enough to forget about people like me. But  
I shared my personal challenges.
“It is hard to explain but the way he listened 
and responded showed me he cared. I felt safe 
and reassured that he was the right mentor, and 
Washington University was the right place,” he said.
Ross’s drive to improve medicine for the poor 
extends beyond his leadership in St. Louis. He 
has assisted in establishing health-care programs 
in Ethiopia and South Africa. Currently, in 
Haiti, Ross is helping to develop a university 
undergraduate program in public health. In the 
U.S., he has worked with the Centers for Disease 
Control and Prevention and other agencies to 
promote cultural awareness among physicians and 
reduce minority obstacles to health care. Through 
the Association of American Medical Colleges 
(AAMC), Ross advocates for increased diversity 
among faculty and students.
“Dr. Ross’s work sits at the nexus of academic 
medicine and public health,” said Juan Amador, 
the AAMC’s director of constituent engagement. 
“He is a national leader in this area.” 
A 2016 AAMC report attributed at least 40 
percent of negative patient outcomes to health 
disparities caused by social and economic factors. 
Such inequities, the report stated, may cause 
“systematic, measurable and avoidable health 
differences between populations that stem from 
social factors such as racism, poverty, lack of 
healthful food, and homophobia that result in 
disproportionate disease and death for the poor, 
racial and ethnic minorities, persons living with 
disabilities, LGBT communities and others.”
“Will Ross spoke about these issues when I first 
met him decades ago,” said William Danforth, 
chancellor of Washington University from 1971 
to 1995. “He was compassionate and authoritative, 
and I remember thinking, ‘Gosh, that young man 
really knows what he’s talking about.’ ”
Hiding from the violence
Ross knows because he lived it. Rarely has he 
spoken publically about his traumatic childhood. 
However, he has decided to share his experiences, 
hoping others will be inspired to persevere to 
achieve their goals. 
Ross’s journey began in a shotgun shack  
with four older siblings, his grandmother and  
Ross often hosts dinner and 
impromptu gatherings for 
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his mother in the small, segregated town 
of Helena, Ark. “I was born into a traumatic 
situation,” Ross recalled. “My mother’s boyfriend 
didn’t like me. My mother had mental health 
issues and was not there for me. I never knew  
my father. However, my grandmother, Willie  
Page, loved me unconditionally and, without 
doubt, was the biggest influence of my life.”
As a toddler, Ross’s family moved 90 miles 
north to Memphis to hide from his mother’s 
abusive boyfriend.
“My first memories were of violence,” Ross said. 
“I remember watching people hurt each other and  
not knowing what to say or how to process it.”
He aimed for inconspicuousness to avoid 
violent interactions. But he was lanky and wore 
big glasses, and his awkwardness and vulnerability 
grabbed attention. Ross fell prey to the older kids 
who assaulted him with rocks and bottles. 
He devoured books from the library. He 
relished mathematical equations like other kids 
enjoyed sports. In kindergarten, he had his first 
memorable experience with medicine. 
Ross’s sister, Helen, 6, had severe asthma 
exacerbated by their mother’s cigarettes. One  
night when the siblings were unsupervised,  
Helen could barely breathe. Ross and his other 
sister, Sherry, 8, helped walk Helen four blocks to 
an emergency room. Once they arrived, health-
care workers groused, glared and ignored them.
“Will someone please take care of my sister?”  
the young Will Ross demanded. “She can’t breathe.”
“If you don’t like it,” a physician told the 
children, “leave.”
They didn’t, and eventually Helen was treated. 
But Ross never forgot the experience.
“I was 5 years old and as serious as I’ve ever been,” 
Ross said. “I told myself that if I ever became a  
doctor, I would never treat a patient so unkindly 
and disrespectfully as the staff had treated us.  
We were kids. We didn’t want Helen to die.” 
Collectively, Ross’s neighborhood experienced 
its lowest point on April 4, 1968. For months prior, 
African-American sanitation workers had been on 
strike to protest economic and social injustices. 
Trash overflowed into the streets. An odor of 
human waste and rotten food prevailed. Flies 
buzzed in swarms.
“Still, we had glimmers of hope,” Ross said.
That’s because Martin Luther King Jr. had  
come to Memphis to support the sanitation 
workers. “He spoke of civil rights,” Ross said.  
“He was leading us toward a better life.”
Standing before a memorial plaque, new medical 
students process the story of how 10-year-old  
Rodney McAllister was killed by a pack of stray dogs 
in a St. Louis park. The stop was part of a weeklong 
orientation focused on health disparities.
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However, shortly after 6 p.m., avowed racist 
James Earl Ray assassinated King at the Lorraine 
Motel, two blocks from Ross’s neighborhood.  
“I remember my mother crying, neighbors  
crying,” Ross said. “I was shattered. We all were.”
For many, grief turned to anger. “Some people 
were armed and rioting,” he said. “They began 
destroying non-black businesses. They burned down 
our neighborhood market run by Chinese-American 
immigrants. Their daughter, Shirley, was my friend. 
We did mathematical equations at the store. After 
the market was destroyed, I never saw her again.  
I have no idea what happened to the family.” 
Ross sighed heavily, gazed at the ground and 
shook his head in disappointment. “Another 
tragic outcome is that the neighborhood never 
recovered,” he said. “To this day, it still looks 
bombed out.”
A safe passage
Ross’s future shifted one afternoon. With blood on 
his shirt — a result of a beating by gang members —
he visited the high school guidance counselor.
The counselor pointed Ross toward Shirley and 
Alfred Wexner, who had established a scholarship 
fund in their deceased daughter’s honor for 
underprivileged kids with academic promise. 
Shirley Wexner helped Ross attend a summer 
program at Phillips Exeter Academy, an elite 
boarding school in New Hampshire. This exposed 
him to higher-level coursework and opportunities 
at elite colleges. Ross lived with the Wexners 
periodically in Memphis, usually during the 
harshest moments at his home.
“The Wexner family offered me a safe passage,” 
Ross said. “In all likelihood, I would be dead if the 
Wexners hadn’t intervened.”
Like many students in the Exeter program, Ross 
was accepted into top-tier universities. He received 
a full-ride scholarship to Yale University, where 
he earned a degree in biology in 1980, and then to 
Washington University, where he earned a medical 
degree in 1984.
Throughout, the Wexner family provided 
financial and emotional support. “We love him,” 
said Shirley Wexner’s daughter, Barrie, who 
is slightly older than Ross. “We are proud he 
continues to help people in need.” 
Encounters with racism
Despite the Wexners’ support, Ross had to overcome  
race-based obstacles. As a second-year medical 
student, Ross was interrogated, handcuffed and 
thrashed against a car hood. Police believed he  
had robbed a store for no reason other than his 
skin color. An hour later, Ross was released when  
a white classmate vouched that he had been in 
class when the robbery occurred.
The incident that most stands out occurred in 
1985, when Ross was an internal medicine resident 
at a hospital affiliated with Vanderbilt University 
in Nashville.
“Around 2 a.m., a middle-age white man came 
into the emergency room with an inflamed knee,” 
Ross recalled. “I told him I needed to drain the pus. 
He said he refused to be treated by a ‘nigger doctor.’ 
Those were his words. I took a deep breath and told 
myself to rise above and take the moral high ground.
“I said, ‘Sir, my name is Dr. Ross. I’m your 
doctor. I’m not a nigger. I will be the person who 
treats you. But first, you owe me an apology.’ ”
The man apologized. In the years ahead, Ross 
would stand up to countless more racist acts. 
“I feel there aren’t that many ‘bad’ people; 
rather, there are those who have been socialized to 
think or act a certain way,” Ross said. “Speaking 
out and showing them the damage done by their 
sometimes unintentional words or deeds can be 
insightful and even therapeutic, as they realize all 
of us have unconscious biases.”
Ross continued: “As associate dean for diversity,  
I feel I should give voice to those who feel dispossessed  
but are either afraid to speak out or don’t know how. 
“By speaking out, we improve health care and 
we uplift humanity.” 
In his nephrology 
practice, Ross makes 
a concerted effort to 
connect with patients 
and understand what’s 
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As a baby, Alexa Reed seemed to be hitting all her 
developmental milestones. When it came time to  
walk, however, she started having trouble. Her right 
foot turned inward and she had a tendency to rise  
up on her tiptoes. 
“For two years I asked her pediatrician if this was 
normal and if I should do something to fix it,” said 
Amy, Alexa’s mom. “We were told that she would  
grow out of it and that no intervention was needed 
aside from reminding her to walk flat-footed.”
Over time, Alexa’s muscles got tighter, she fell 
down frequently and increasingly relied on toe-
walking. Wearing braces for several years and 
undergoing weekly physical therapy to stretch her 
tight legs did not improve the situation. 
At nearly 4 years of age, Alexa finally received  
a definitive diagnosis: spastic diplegic cerebral palsy  
(CP), a chronic neuromuscular disorder that causes  
tightness and spasms in the extremities. Most commonly 
caused by lack of oxygen and early damage to the 
brain, spastic CP accounts for almost 80 percent of  
CP cases. 
‘Future we only 
dreamed of ’
Outlook  25
A renowned surgeon is restoring  
mobility in children with cerebral palsy 
B Y  G A I A  R E M E R O W S K I
Esme “Ezzy” Hodge and her  
parents traveled from Bristol, 
U.K., for selective dorsal  
rhizotomy surgery with  
neurosurgeon T.S. Park, MD.
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Soon after Alexa’s diagnosis, the Reeds moved from Los Angeles to St. Louis for a new job and to be closer to family — not realizing 
that Washington University Medical Campus 
is home to T.S. Park, MD, a world-renowned, 
uniquely qualified pediatric neurosurgeon who 
specializes in treating spastic CP.
Post-surgery, Alexa, now 9, has full function 
and enjoys hiking, soccer and hanging out with 
friends. In Alexa and in thousands of other kids 
worldwide, Park has restored the ability to walk. 
Not your average neurosurgeon
Park, the Shi H. Huang professor of neuro- 
surgery, is a pioneer in the use of selective dorsal 
rhizotomy (SDR), a spinal surgery that he performs 
at St. Louis Children’s Hospital. In the procedure, 
Park severs the nerves that cause spasticity.
Park has been performing SDR for 30 years, 
treating more than 3,700 patients from 47 states 
and 73 countries. Of those cases, only nine have  
ever required readmission (four for wound 
infections, five with spinal fluid leaks).
Amy found out about Park from an in-home 
physical therapist. 
“It was glaringly clear that our move from  
Los Angeles back home to St. Louis was somewhat 
serendipitous,” Amy said. “We were exactly where we 
needed to be to have the most skilled and successful 
surgeon on the planet be the one to end the grasp 
that spasticity had on our daughter for good, and 
give her a future we had only dreamed of.”
Born in Bristol, U.K., Esme, or Ezzy (as she 
likes to be called) Hodge, had to come a bit 
farther for help. Ezzy’s parents noticed their baby 
daughter wouldn’t reach up for a cuddle and had 
trouble balancing independently. An MRI at age  
2 revealed Ezzy had suffered a brain injury during 
birth. Like Alexa, she was diagnosed with spastic 
diplegic CP. 
“We were told she would never walk,” said Ezzy’s 
mom, Angela. “As parents we were truly devastated.” 
Angela found Park’s name during an online 
search for potential treatments. “I knew then 
I would do whatever it took to get Ezzy this 
amazing surgery and prayed Dr. Park would say 
yes to helping our little girl, as he was her only 
chance,” Angela said.
In the initial patient evaluation, Park’s team tells 
the family what type of outcome to expect: Will 
the child walk independently, or with crutches or a 
walker? Will the child be able to run and jump? 
“I’m fairly sure we are the only ones who can 
give such a precise prediction,” Park said. “Our 
prediction rate is very high — 85 percent correct.”
Constantly seeking 
improvements
Severing spinal nerves that cause spasticity has been 
going on since the 1900s. But SDR did not make its 
way to the U.S. until 1986. Once Park learned about 
it in 1987, he began using the technique. By 1991,  
he made some key improvements. 
The procedure originally involved cutting 
through five to six vertebrae in the lower spine to 
access the nerves causing spasticity. Park refined 
the process so he only needed to cut one lower 
vertebra. This less invasive method causes no long-
term spinal problems and allows Park to perform 
the surgery on children as young as 2, who heal 
quickly, as well as patients as old as 50, whose 
spines would otherwise never heal completely.
Though Park performs the bulk of SDR 
surgeries on children, he also has operated on 130 
adults — more than any other doctor in the world 
— at Barnes-Jewish Hospital. 
Post-surgery, Alexa 
Reed, 9, of St. Louis, 
has regained full  
function. 
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Neurosurgeons from across the globe come  
to observe his surgical methods and techniques. 
And Park trains fellows at Children’s Hospital in 
the procedure.
Park also has published nearly 40 papers about 
the surgery in scientific journals. Because his team 
is the only one that has performed SDR surgery 
for three decades, it is in a unique position to 
study long-term outcomes. 
Just this year, Park and his colleagues 
published two papers: In one, they followed 
95 patients between the ages of 23 and 37 who 
had SDR surgery 20 to 28 years ago, and, in 
another, they surveyed 294 adult patients who 
had received SDR surgery as children. Both 
studies showed overwhelmingly positive results. 
The improvements these patients experienced in 
walking and in general quality of life after SDR 
surgery extended through adulthood and they 
reported no long-term side effects.
“We can clearly say SDR surgery is the only 
treatment that can remove spasticity permanently. 
No other treatment can do this,” Park said.
“He developed — really single-handedly — 
the operation of selective dorsal rhizotomy for 
cerebral palsy,” said Ralph Dacey, MD, the chair 
of neurologic surgery, in a 2017 tribute video 
honoring Park. “And not only did he develop 
the processes around doing that procedure very 
effectively and safely, but he was able to prove its 
efficacy in a series of papers that have become 
landmark studies.”
Results “like magic”
The SDR surgery typically lasts three to four hours, 
followed by a five-day hospital stay. Then, the 
tough rehabilitation work begins. This includes 
daily physical therapy with Children’s Hospital 
therapists. Out-of-country patients like Ezzy are 
expected to stay in St. Louis for about a month 
and then they must continue intensive physical 
therapy at home for a few more months while 
Park follows the progress remotely. 
Ezzy’s improvements began almost  
immediately after surgery.
“Like magic before our eyes, she made daily 
improvements,” Angela said this past October.  
“In just two short weeks, she has managed to  
walk with a cane, something I wouldn’t have 
believed unless I saw it with my own eyes.”
Some children, such as Alexa, need an additional 
orthopedic surgery to lengthen their muscles and/
or tendons, which shorten from prolonged disuse.
Park refers these patients to pediatric 
orthopedic surgeon Matthew Dobbs, MD, who 
has developed a minimally invasive muscle- 
and tendon-lengthening surgery that further 
improves patients’ range of motion and mobility.
The combined surgeries offer dramatic 
improvements in patients with severely impaired 
mobility, Park said.
Five months post-op, Alexa started playing sports 
like soccer and even participated in a 5K race.  
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Among the many patient  
tributes to Park: (top) a  
children’s book titled  
“Sir Dr. Park and the Dragon, 
Spasticity” and (bottom) 
a doll made in his likeness.  
Park celebrates with a gathering of 
former patients in the U.K. Patient 
families in other countries often throw 
welcome parties for Park whenever he 
visits to perform consults. 
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Nine months after Alexa’s surgery, Amy reported: 
“Dr. Park joyfully told my daughter, ‘You never 
have to see my face again!’ She was released from 
physical therapy and allowed to simply be a kid.”
A global impact
To help spread the word about the life-changing 
surgery, in 2010, Park and his team started the 
Selective Dorsal Rhizotomy-St. Louis Children’s 
Hospital Facebook page. It has since amassed 9,000 
followers. Before long, family-run Facebook pages 
championing Park’s expertise began cropping up 
— in Brazil, Korea and dozens of other countries. 
Park checks the Children’s Hospital and 
country-specific Facebook pages multiple times 
a day, replying to questions, posting comments, 
medical literature and information to help parents 
and patients navigate the complex world of CP.
Park dedicates time every year to travel the 
world and examine children with CP to see 
whether they qualify for SDR surgery. To consult 
with these patients, he visits hospitals, clinics, 
sometimes even hotels, like the one owned by his 
brother in Korea. 
Park also tirelessly advocates for health 
insurance policies to cover the surgery. He’s given 
talks, for example, in Hungary to the country’s 
national health insurance program director, and 
even testified to a British parliament member.
To help make the surgery financially accessible, 
especially for international families, Park lobbied 
Children’s Hospital to set a fixed rate of $40,000 
for any patient paying out of pocket. Because of 
his undeniably positive outcomes, the hospital 













Surgery patients from 
around the world
Park has performed selective dorsal rhizotomy on more than 
3,700 patients from 47 states and 73 countries. In most cases, 
the procedure permanently removes spasticity, enabling the 
patient to walk again and resume age-appropriate activities. 
As a result, patient families continually send Park photos 
documenting the progress. Pictured above: former patients, 
their home country and year of surgery. 
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or years fundraising for the surgery, this fixed 
rate provides peace of mind. Park does his part by 
charging only $100 for initial consults and nothing 
for follow-up visits.
Motivated by his international patient base, 
Park also worked to improve the hospital’s 
interpreter service — something that benefits 
every non-English-speaking patient who comes 
through the doors. 
Beyond grateful
“At the end of the day I know T.S. Park is what we 
call a guardian of childhood,” said Joan Magruder, 
St. Louis Children’s Hospital president, in a 2017  
tribute video honoring Park. “He has done 
everything imaginable to make sure that every 
child has the opportunity to be a child and to  
live their childhood to the absolute maximum.”
This year, Missouri Gov. Eric Greitens and 
St. Louis Mayor Lyda Krewson declared Sept. 9 
as Dr. T.S. Park Day. The day was marked by a 
symposium in Park’s honor.
Families from every corner of the globe make 
videos showing their children’s growth and 
progress and regularly post them on the SDR 
Facebook page — something Park said he loves to 
see. “I’ve befriended a number of parents,” Park 
said. “We have personally become very connected.” 
It’s a bond that Amy, and thousands of  
parents like her, acknowledge with gratitude.  
“The possibilities for Alexa are endless now,”  
Amy said. “My daughter will live a full healthy 
life, free from spasticity, thanks to Dr. Park.  
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A$10 million gift from longtime benefactors George  and Debra Couch is supporting one of the School  of Medicine’s highest priorities: research advances in 
personalized medicine. In recognition of the couple’s pledge,  
the university has named the newest research building on  
the medical school campus — a six-story facility located at  
4515 McKinley Avenue — the Debra and George W. Couch III 
Biomedical Research Building. The couple was honored during  
an Oct. 6 dedication ceremony. 
Personalizing medicine
$10 million gift drives 
genome engineering 
into therapeutic realm 
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The gift establishes an endowed fund dedicated to 
initiatives aimed at revolutionizing the way disease is 
diagnosed, treated and prevented. Because personalized 
therapies often are rooted in a person’s genetic makeup, the  
new fund provides support for the Genome Engineering  
Center (GEC). With the center’s expertise in the latest 
genome-editing technologies, such as the ability to reprogram 
stem cells, university scientists are able to create precise 
cellular models of disease. 
“We are deeply grateful to Debra and George Couch  
for their extraordinary generosity and for their commitment 
to improving human health,” said Chancellor Mark S. 
Wrighton. “Their gift will support cutting-edge research 
by our talented faculty in pursuit of personalized medical 
solutions for patients. With this generous support, the 
Genome Engineering Center will be even better positioned 
as a resource for our investigators, who are working at the 
forefront of the biomedical sciences.” 
For the past 11 years, Couch has served on Washington 
University’s Board of Trustees. He also has served as a 
member of the School of Medicine National Council 
for nearly two decades — giving him a close-up view of 
breakthroughs that have transformed the way scientists  
and physicians approach disease, from the sequencing of  
the human genome to research illuminating the key roles  
of the immune system and the gut microbiome in conditions 
such as cancer, obesity and malnutrition.
“It has been a privilege to be associated with the national  
council and be exposed to renowned faculty members 
who are making such a difference in the health of people 
around the world,” he noted. “As my wife, Debra, and  
I began to think about our own legacy, we knew we 
wanted to help advance their work.” 
Powerful technology
Jeffrey D. Milbrandt, MD ’78, PhD, the James S. McDonnell  
Professor of Genetics and head of the McDonnell Department  
of Genetics, established the Genome Engineering Center 
in 2013. This gift will help advance the center’s innovative 
research and support services, particularly providing 
investigators with the ability to leverage a powerful DNA 
editing tool known as CRISPR-Cas9. 
Developed only five years ago, CRISPR-Cas9 is 
revolutionizing biomedical research. “The technique allows  
us to edit genomes in a very precise way,” Milbrandt said. 
“You use a computer to identify the exact DNA stretch  
you want to alter and then execute the change rapidly  
and efficiently. And you can use the same toolkit on  
any organism.”
GEC experts employ CRISPR-Cas9 and other gene-
editing techniques to create cells and cell lines with 
specific mutations and generate libraries of mutations  
Personalizing medicine
(Top) Chancellor Mark S. Wrighton delivered remarks at the dedication 
ceremony for the newly named Debra and George W. Couch III Biomedical 
Research Building. (Middle) A portrait of Debra and George Couch will 
hang in the building. (Bottom from left) Craig Schnuck, chair of the 
Washington University Board of Trustees; Wrighton; Debra Couch;  
George Couch; David Perlmutter, executive vice chancellor for medical 
affairs and dean of the School of Medicine; and Jeffrey Milbrandt, head  
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that help investigators study disease processes, identify  
drug targets and advance new treatments.
The center also provides expertise in the manufacturing 
of induced pluripotent stem cells (iPSC). These are cells 
taken from skin, urine or blood and regressed back into stem 
cells. From there, they can be made into nearly any cell type. 
When taken from a person with a particular disease, these 
converted cells still model the disease process. This opens 
up new research opportunities, particularly in previously 
inaccessible cell types, such as neurons.
“The gift will serve as a catalyst for developing biological 
systems that model diseases in a highly personalized way 
and for facilitating the development of new diagnostics and 
therapeutics from biologically validated data — our best hope 
for discovering precise ways to alleviate human suffering,” 
said David H. Perlmutter, MD, executive vice chancellor for 
medical affairs and dean of the School of Medicine. 
The GEC is a world leader in the production of  
engineered cells and cell lines. Since its inception, the  
center has created more than 300 CRISPR-modified cell 
lines, including more than 100 derived from iPSCs. 
The center has provided services to 200 laboratories at 
Washington University and about 70 academic institutions 
and corporations around the globe. The center helps to 
catalyze the work of university researchers who do not have 
access to this groundbreaking technology in their own labs. 
With a thriving GEC as a resource, researchers can better 
compete for federal grant funding and departments can 
attract and retain top faculty.
According to Milbrandt, genome engineering and 
iPSC technologies are developing at breakneck speed. 
“To keep pace, we must constantly invest in research 
and development,” he said. “This endowment will allow 
us to implement new techniques, invest in highly skilled 
personnel, and purchase equipment that will help us move 
genome editing into the therapeutic realm.” 
In addition to the GEC and the Department of Genetics, 
the Couch Biomedical Research Building is home to 
numerous initiatives and centers, including the Edison 
Family Center for Genome Sciences and Systems Biology, 
the Center for Cellular Imaging, the Center for Multiple 
Myeloma Nanotherapy, the Optical Radiology Lab, and the 
Molecular Imaging Center, and includes research space for 
the Center of Regenerative Medicine and the departments  
of Medicine and Radiology.
Inspired to help others
For more than three decades, the Couch family has provided 
significant support to Washington University. George Couch 
attended high school in St. Louis before earning a bachelor’s 
degree in economics from Stanford University and a master’s 
degree in business administration from Harvard University. 
He is founder, chairman, president and chief executive officer 
of Couch Distributing Company in Watsonville, California, 
and his wife, Debra, owns the Debra C clothing boutique in 
Carmel, California. 
The family’s commitment to the school began in 1986 
with a very personal motivation — the endowment of the 
Gregory B. Couch Professorship in Psychiatry in memory  
of George’s brother, who developed schizophrenia in his 
teens before dying unexpectedly from a heart attack at age 
31. A Washington University psychiatrist treated Gregory 
while the family was living in St. Louis.
“Gregory was a wonderful person,” George Couch 
said. “His dream had been to attend medical school 
and become a doctor, so my family decided to endow a 
professorship in his memory at the School of Medicine.” 
Deanna Barch, PhD, a renowned scientist who 
studies cognitive and language deficits in disorders 
such as schizophrenia, holds the professorship. 
With the endowed fund in personalized medicine, 
the Couches saw a unique opportunity to help 
advance the quality of life for people around the 
globe by contributing to the next phase of discovery.
 “If we are able to help mitigate suffering in 
any way, that’s a larger contribution to humanity 
than Debra and I ever envisioned we would have,” 
George said. “We feel very fortunate that we can do 
something that has such potential to help others.” 
Information for this story was provided by Mary Lee,  
Julia Evangelou Strait and Channing Suhl.
A L U M N I  &  D E V E L O P M E N T
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1950S
Wolff Kirsch, LA ’51, 
MD ’55, HS, serves 
as director of the 
Neurosurgery Center 
for Research, Training, 
and Education at Loma 
Linda University in 
California. Loma Linda 
University Health honored Kirsch with 
the Distinguished Investigator Award in 
May 2017. His career accomplishments 
include: obtaining more than $10 million in 
research grants and more than 40 U.S. and 
international patents, identifying two new 
amino acids in nature, publishing 200-plus 
papers and mentoring many graduate and 
medical students.
1960S
Paula Clayton, MD ’60, recently moved to 
St. Louis City and is living within walking 
distance of the medical school, where she 
hopes to volunteer during the academic year.
Ira J. Kodner, LA ’63, 
MD ’67, was chosen 
by the St. Andrew’s 
Charitable Foundation 
as a 2017 Ageless 
Remarkable Saint 
Louisan. These awards 
honor older adults 
who remain an active force in the St. Louis 
metropolitan area and recognize the continued 
achievements of those who have made and 
continue to make a difference in lives.
Hunter Heath, MD ’68, volunteers one day 
per week at Indiana University School of 
Medicine, and recently began volunteering 
as a workforce development consultant 
and adviser/editor on grant submissions 
for Fathers and Families Center, a nonprofit 
agency in Indianapolis, Ind. Fathers and 
Families seeks to reconnect a generation 
of young men with the tradition of 
responsible fatherhood through assistance 
in finishing high school or trade school, 
earning and keeping employment, and 
more. In his spare time, Heath enjoys 
learning how to play the guitar.
1970S
James M. Mick, MD ’70, retired nearly four 
years ago, though he still enjoys serving 
as the medical director of the Partners 
for Healthy Students program at Yavapai 
Regional Medical Center in Prescott, Ariz. 
He recently traveled to Spain with his wife, 
Francine, and classmate Francisco “Paco” J. 
Garriga, MD ’70, and reports that all had a 
great time. Mick enjoys spending time in 
church activities and with his family.
Timothy J. Ley, MD ’78, HS, a leukemia 
researcher and hematologist at WUSM, 
has received a seven-year, $6.4 million 
Outstanding Investigator Award from the 
National Cancer Institute of the National 
Institutes of Health (NIH).
1980S
Jack Turman, PT ’84, was excited to join 
the faculty at Indiana University’s Richard 
M. Fairbanks School of Public Health as a 
professor in the Department of Social and 
Behavioral Sciences. Turman is dedicated to 
research, teaching and outreach to improve 
birth and infant development outcomes in 
local and global communities.
Bruce Alter, PT ’86, was awarded 
Therapist of the Year at the annual Therapy 
in Educational Settings Conference in April 
2017 from the Douglas Education Service 
District in Eugene, Ore.
Christine Kushner, PT ’87, of Homer Glen, 
Ill., proudly announced that her daughter 
was accepted into the Program in Physical 
Therapy at Washington University.
1990S
Angela L. Brown, MD ’92, a hypertension 
management specialist within the WUSM 
Cardiovascular Division, was selected to 
receive the 2017 Hugh D. McCulloch Award 
from the Greater St. Louis Division of the 
American Heart Association. 
Find your friends.
Classnotes are organized first by  
year of degree/training completion 
and then in alphabetical order. 
How about you?
Share your news via the online 
form at wumcnews.org/classnotes. 
Submissions will be printed in 
a subsequent issue of Outlook 
magazine as space allows. Photos 
are welcome.
C L A S S N O T E S
John C. Barber, MD ’65, of Pittsburgh, Pa., released a new book, “The One-Eyed Surgeon With Only One 
Thumb: Adventures With My Dad, Harry C. Barber, MD, 
FACS,” in which he recounts how his father lost a thumb 
and one eye in a hunting accident at age 17, but per-
severed to graduate from the School of Medicine and 
have a successful career as a surgeon. Harry Barber also 
spent two years in the Arctic Circle during World War II  
repairing injured soldiers’ injuries before returning 
home to Bloomington-Normal, Illinois. Harry Barber 
practiced during an era of $5 office visits and $8 house 
calls — although he was quick to reduce his fees and 
care for the indigent.
Barber tributes father
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Frank Puc, PT ’94, 
was named CEO at 
Revolution Physical 
Therapy Weight Loss 
based in the greater 
Chicago area.
Imran Zoberi, MD ’96, HS ’01, is a 
professor of radiation oncology at the 
School of Medicine, chief of the breast 
cancer service and chief of hyperthermia 
service in radiation oncology and serves as 
clinical director for radiation oncology at 
Barnes-Jewish West County Hospital.
Dawn Ebach, MD 
’98, was promoted 
to clinical professor 
at the University of 
Iowa Carver College 
of Medicine July 1, 
2017. She is a pediatric 
gastroenterologist in the 
Stead Family Department of Pediatrics.
2000S
Julie K. Schwarz, MD ’04, PhD ’04, HS, 
has been named director of the Cancer 
Biology Division in the Department of 
Radiation Oncology at WUSM.
Joel C. Geerling, MD 
’08, PhD ’08, is an 
assistant professor 
of neurology at the 
University of Iowa 
Hospital and Clinics.
Rahul Kasukurthi, 
MD ’10, GM ’10, looks  forward to 
beginning his first post-fellowship 
attending job in plastic surgery at  
Kaiser Permanente in Portland, Ore.
2010S
Aaron Norris, MD ’12, PhD ’12, was 
selected to receive a Foundation for 
Anesthesia Education and Research 
(FAER) Mentored Research Training Grant. 
The grant is a two-year faculty award to 
“help anesthesiologists develop the skills, 
preliminary data for subsequent grant 
applications and research publications 
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Audrey Shillington, 
MSW ’87, PhD ’87, 
GM ’93, director of the 
School of Social Work at 
Colorado State University 
since 2012, also is 
assuming responsibilities 
as the associate dean 
for academic affairs in the College of 
Health and Human Sciences. Additionally, 
she is professor of epidemiology at the 
Colorado School of Public Health. She has 
published in the areas of psychometrics, 
epidemiology, prevention and intervention 
work aimed at adolescent and young adult 
risk behaviors. She has been principal 
investigator and co-investigator on National 
Institutes of Health, National Institute on 
Drug Abuse, National Institute on Alcohol 
Abuse and Alcoholism state grants totaling 
more than $14 million. Her current work 
is focused on intervention and prevention 
efforts related to the changing landscape in 
legalized recreational marijuana use.
Occupational therapy alumna Kristin Will, OT ’14, is transitioning from  providing clinical care in the U.S. to working alongside the Musana  
Community Development Organization to start an occupational therapy clinic  
and outreach program in Iganga, a town in the eastern region of Uganda. Will  
plans to collaborate with Musana over a 15-month period to expand services  
in a health center and bridge social and medical projects. 
Musana’s mission is to provide the community with locally owned and  
operated sustainability projects, including schools, business loans, farming  
and social work. The organization has been working in the Ugandan community  
of Iganga for more than nine years. 
From an early age, Will’s parents exposed her to the need for international aid,  
and in high school she traveled to Kenya to assist with a medical education team.  
“I knew that I wanted to work internationally ever since,” she said.
During her time at the School of Medicine, Will sought to use her training and 
skills to better understand the many internal and external factors that influence a 
person’s life, from cognition and physical state to social capital and cultural influences.  
“I am excited to use the skills and knowledge that occupational therapy has given  
me to better understand the people in developing communities and to work together 
with them to bring sustainable development to their communities,” Will said.
Will helps establish Ugandan 
occupational therapy clinic
Kristin Will, OT ’14, plays with children in a small Ugandan village. 
C L A S S N O T E S
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needed to become independent 
investigators.” Norris received the FAER 
grant for his project titled “Isoflurane 
Activated Neural Circuits,” which will 
examine the functional relationship 
between neurons activated by isoflurane 
and neurons active during sleep.
Amit Patel, MD 
’12, HS ’13, and  
Ami Patel, MD ’12, 
HS ’15, proudly 
announce the birth 
of their son, Avi 
Amit Patel, born 
on Aug. 4, 2017.
Lora Melman, LA 
’98, HS ’13, is a 
fellowship-trained, 
board-certified and da 
Vinci robot-certified 
specialist surgeon 
in New Jersey who 
is focused on providing cutting-edge 
surgical care by combining enhanced 
recovery methods with minimal-access 
techniques. She feels fortunate to have 
trained with prominent leaders in hernia, 
bariatrics and foregut surgery and her 
specific areas of interest include surgical 
weight loss for obesity, repair of all 
types of abdominal wall hernias, sport 
hernias, repair of diaphragmatic and 
hiatal hernias, treatment of esophageal 
dysmotility disorders, reflux disease 
and minimal-access adrenalectomy 
and splenectomy. Melman, an expert 
in the realm of hernia repair, is a widely 
published author of peer-reviewed 
literature on hernia repair biomaterials.
Yi Wang, MD ’13, began working 
as a general pediatrician at Legacy 
Community Health in Houston.
Stephanie Weyrauch, 
GM ’15, DPT ’15, 
recently held a legislative 
day at her private practice, 
RehabAuthority Physical 
Therapy in Thief River 
Falls, Minn. The staff 
welcomed Minnesota Congressman Collin 
Peterson while the team advocated for 
several issues, including physical therapy 
as an alternative to opioids for treatment of  
chronic pain, increased access to physical 
therapy services in rural areas, and repeal 
of the Medicare Therapy Cap. Local news 
reporters also attended and captured 
video on how physical therapy has helped  
some of Weyrauch’s patients wean off 
opioids and live a more fulfilling life.




PhD ’99, now writes 
and publishes science 
thrillers. A trainee 
of the Medical Scientist Training 
Program, Rogers initially assumed  
she would work as a research 
scientist. As she began teaching 
undergraduate microbiology 
and molecular biology courses at 
California State University in the mid 
2000s, Rogers found that she was 
“bursting with story ideas.”
Acknowledging that she didn’t 
know how to write fiction, Rogers 
began by writing critical reviews of 
any science thriller novels that she 
could find and launching a website, 
ScienceThrillers.com. Now, she is 
author of three published novels: 
“Petroplague,” her debut book, 
“Reversion” and “The Han Agent.”
 “My goal with the science is 
to make it entirely plausible and 
accessible to the non-technical 
reader, while also keeping it as 
accurate as the story allows,” Rogers 
said. All of her books feature 
interesting microbes, a female 
scientist as the protagonist, and  
at least one lab experiment that 
plays a critical plot role.
More information can be  
found at ScienceThrillers.com  
and AmyRogers.com.
Rogers pens  
science thrillers
  
O B I T U A R I E S
Jeffrey Fletcher Moley, MD, a 
highly regarded professor of 
surgery, chief of the Section 
of Endocrine and Oncologic 
Surgery and associate director 
at Siteman Cancer Center at 
Barnes-Jewish Hospital and 
Washington University School 
of Medicine, died Sunday,  
Oct. 15, 2017, at his home in 
Kirkwood following a sudden 
cardiac event. He was 64.
He had been married for 30 years to  
Kelle H. Moley, MD, the James P. Crane 
Professor of Obstetrics and Gynecology.
For more than two decades, Moley was a 
pioneer in researching and treating Multiple 
Endocrine Neoplasia (MEN), rare inherited 
syndromes that often cause an aggressive 
form of thyroid cancer and other endocrine 
diseases, particularly in those at young ages.
Moley was part of a team that identified 
the genetic mutations responsible for MEN 
syndromes and advanced a preventive 
procedure that includes surgical removal of 
the thyroid gland. Moley also operated on 
patients with recurrent thyroid cancer and 
other endocrine diseases.
“Jeff was a masterful surgeon,” said 
Timothy J. Eberlein, MD, the Spencer T. and 
Ann W. Olin Distinguished Professor, head of 
the Department of Surgery, director of 
Siteman Cancer Center and surgeon-in-chief 
at Barnes-Jewish Hospital. “He delicately 
performed surgery to remove the thyroid 
gland in young children — some only a few 
months old — who were destined to develop 
an inherited form of thyroid cancer. The 
margin of error in these procedures is almost 
none, and Jeff was simply remarkable.”
Besides treating patients at Barnes-Jewish 
and St. Louis Children’s hospitals, Moley 
worked for more than three decades for the 
VA St. Louis Health Care System. At each of 
the hospitals, Moley helped train residents 
and medical students.
In addition to his wife, Moley is survived 
by: three sons, Patrick, Charles and John; his 
mother, Janis Walton Moley; a sister, Janis 
McCarthy; and a brother, Roger Moley.
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Emerson Chairman Emeritus Charles F. Knight, a major benefactor 
of Washington University and longtime member of its Board of 
Trustees, died Tuesday, Sept. 12, 2017, of complications from 
Alzheimer’s disease at Missouri Baptist Medical Center. He was 81.
Knight, who was chief executive officer at Emerson Electric  
Co. for 27 years, helped shape the present-day Washington 
University, according to Chancellor Mark S. Wrighton.
“Chuck Knight was a loyal and dedicated friend of Washington 
University for more than 40 years. His extraordinary generosity, 
support and vision can be felt and seen throughout our 
campuses,” Wrighton said.
“He, along with his wife, Joanne, showed an unwavering commitment to advancing 
the university as well as the St. Louis community. Whether through helping establish Olin 
Business School as one of the premier institutions of business education and research in 
the world, or his critical support in building the Alvin J. Siteman Cancer Center into the 
country’s third-largest cancer center, Chuck was dedicated to supporting institutions that 
improve lives and advance knowledge,” he added.
A deep commitment to supporting medical research drove his support for the School 
of Medicine, where he had served on its National Council.
He and his wife established the Charles F. and Joanne Knight Distinguished Professorship 
in Orthopaedic Surgery, providing top-level teaching and research in this growing area.
The Joanne Knight Breast Health Center and Breast Cancer Program were dedicated in 
April 2007 in appreciation of the generosity and leadership of the Knights in supporting 
advancements in breast cancer research, patient care and community outreach at the 
Siteman Cancer Center at Barnes-Jewish Hospital and the School of Medicine.
The Knights, longtime leaders in supporting Alzheimer’s disease research, made a 
major commitment to the School of Medicine to advance Alzheimer’s research. The 
university recognized the couple in 2010 by naming its world-renowned Alzheimer’s 
Disease Research Center in their honor.
He served in a number of leadership capacities for Barnes Hospital, overseeing the 
creation of Barnes-Jewish Hospital and helping engineer the formation of BJC Health 
System, now known as BJC HealthCare.
He served as board chairman of the BJC system in the 1990s and was named emeritus 
chairman for life of Barnes-Jewish Hospital.
In 2002, Barnes-Jewish Hospital opened the Charles F. Knight Emergency and Trauma 
Center, a 52,000-square-foot facility offering 61 beds and a comprehensive environment 
for specialized care.
In addition to his wife, he is survived by children Lester Knight of Chicago, Anne 
Knight Davidson of St. Louis, Steven Knight of Seattle and Jennifer Knight Beckmann of 
Chicago; 12 grandchildren; and three great-grandchildren.
Denise Thomas, a medical assistant for 28 years in the Division 
of Hematology, died July 4, 2017, in St. Louis. Thomas, 52, died 
several days after suffering a stroke at her home.
Thomas was on track to earn a bachelor’s degree in health-
care management from University College in December. The 
college plans to award her degree posthumously.
Thomas is survived by her husband, Theo Thomas; her 
sons, Cory J., Phillip A. and Andrew A. Thomas; her sister, 
Vinissa Thomas; her 
brothers, Norval L. 
Washington, Milton Bell, 
Lamont Thomas and Frank P. Thomas; and six 
grandchildren.
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1930S 
Yvonne Bost Pickett, NU ‘38; Aug. ‘17
1940S
Ralph Berg Jr., MD ‘45; June ‘17
Juanita G. Brownback, NU ‘48; Aug. ‘17
J. Richard Compton, LA ‘40, MD ‘43; Aug. ‘17
Richard A. Jones, MD ‘43; Aug. ‘17
Jean J. Norwood, NU ‘43; Aug. ‘17
Irene M.C. Restad, OT ‘48; June ‘17
Harold Speert, HS ‘42; Feb. ‘17
William B. Stocker, DE ‘46; Aug. ‘17
1950S
Edwin E. Carter, MD ‘54; July ‘17
Rudolph E. Catanzaro, LA ‘49, MD ‘50; Aug. ‘17
Richard L. Ellis, DE ‘51; Aug. ‘17
William Y. Eubank, MD ‘53; July ‘17
Nancy Ferreira, OT ‘56; March ‘17
Ann Feldman Freeman, PT ‘59; Aug. ‘17
Guy T. Gillespie Jr., HS ‘54; June ‘17
Bill L. Hamilton, HA ‘56; Feb. ‘17
John W. Hard, LA ‘50, MD ‘54; Sept. ‘17
Bertram W. Justus, MD ‘57; May ‘17
M. Richard Katz, LA ‘52, MD ‘55; June ‘17
Leslie E. Long, DE ‘57; Sept. ‘17
Roy A. Nelson Jr., DE ‘57; Feb. ‘17
Havner H. Parish Jr., MD ‘56; June ‘17
Gonzalo T. Roman Jr., HS ‘59; Aug. ‘17
Paul A. Rubenstein, MD ‘57; July ‘17
Sidney L. Saltzstein, HS ‘58; May ‘17
Semon J. Sandven, MD ‘51; July ‘17
Jack C. Tippett, LA ‘49, MD ‘53; Aug. ‘17
Earl J. Wipfler Jr., LA ‘52, MD ‘55; Aug. ‘17
1960S
Martha Anne Coleman, GN ‘65; Apr. ‘17
Susan Hackman Kingston, NU ‘67; Sept. ‘17
Anne P. Lanier, MD ‘66; May ‘17
Robert T. Miller, MD ‘63; March ‘17
Paul M. Packman, LA ‘59, MD ‘63; Sept. ‘17
Symuel H. Smith, UC ‘61, HA ‘65; June ‘17
1970S
Richard Lewis Baron, MD ‘76; May ‘17
Jaswinder Kaur Ghuman, HS ‘79; Aug. ‘17
Pamela A. Pedersen, GR ‘71; Aug. ‘17
Robert Dale Rounds, DE ‘74; March ‘17
Thomas P. Wharton Jr., MD ‘71; April ‘17
1980S
Jeanne Dahlen Lewis, MD ‘82; May ‘17
Richard Marias, DE ‘84; Aug. ‘17
1990S
Pamela Jo Smith, OT ‘92; June ‘17
For full obituaries, visit: 
wumcnews.org/obits
174295_p30-36_IBC_MAD_v9_cc17.indd   36 12/1/17   12:32 PM
outlook.wustl.edu Outlook  37
Standing in the cornfields near his Carlinville, Illinois home, a young James Wittmer, MD ’57, MPH, watched in 
amazement as planes flew overhead. 
A lifelong curiosity about the world around 
him — along with extra-
ordinary leadership abilities 
— drove Wittmer to work on 
some of NASA’s first human  
spaceflight programs, to 
lead Vietnam War triage 
operations, to travel the globe 
as an attending physician on 
congressional trips, and to 
direct health and safety in  
top U.S. corporations.
“Even as a child, I knew 
there was so much out there 
in the world, and I needed to 
see it and do it all,” Wittmer said. “Washington 
University opened up the world to me — the one 
I’d only read about.”
Wittmer, a retired colonel, attended under-
graduate classes at Washington University and  
earned a medical degree from its School of  
Medicine. He and his wife, Juanita, an accomplished  
artist, are parents to three grown daughters and 
live in Texas. Recently, the couple committed 
estate gifts to fund professorships and scholarships 
on both campuses — supporting personalized 
medicine initiatives at the School of Medicine and 
the Driving Discovery project in Arts & Sciences.
As an undergraduate, Wittmer excelled in and 
out of the classroom, participating in intramural 
sports and Thurtene Honorary. During his medical  
school admission interview, he met C. Barber 
Mueller, MD, an educator and surgeon who had 
grown up on the same Carlinville street. Mueller 
became a valued mentor to Wittmer.
Following a surgical internship at the 
University of Virginia Hospital in 1958, Wittmer 
was drafted. He served two years as a U.S. Air 
Force flight surgeon and completed the USAF 
Aerospace Medicine Specialty Training Program. 
The first year of this training involved earning 
a master’s degree in public health from Harvard 
University. He remembers being “swept up” in  
the country’s space flight intrigue post-Sputnik. 
Wittmer has the distinction of working on 
NASA’s second human spaceflight program, Project 
Gemini, from 1965-67. In this pre-satellite era, 
NASA relied on crews deployed to ships around the 
world for real-time assessment of the astronauts. 
Wittmer had minutes to check astronauts’ 
vital signs and physiological responses as their 
spacecraft passed overhead and relay that data to 
Mission Control Center in Houston. He did this 
by monitoring a console that received information 
from electrodes attached to the astronauts’ bodies. 
After a 21-year Air Force career, Wittmer 
moved to New York, spending two years as U.S. 
medical director for Mobil Oil Corporation and 
12 years with ITT Corporation, rising to corporate 
vice president for health, environment and safety. 
Flight surgeon’s storied career
“Washington 
University 
opened up the 
world to me.”
B Y  C H A N N I N G  S U H L
James Wittmer in his many roles (clockwise from left): on a congressional trip to Cairo in 1975;  with an aero club Cessna 150 in 1962;  
caring for a hurricane evacuee on a rescue helicopter in 1968; and in pressure suit training at a simulated altitude of 68,000 feet in 1962.
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